Bluejay Diagnostics (BJDX) vs Nexalin Technology (NXL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bluejay Diagnostics is the larger company by market cap ($3.7 million vs $3.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BJDX | NXL |
|---|---|---|
| Share price | $0.8239 | $3.63 |
| Market cap | $3.68M | $3.01M |
| 1-day change | +1.02% | -11.68% |
| EPS (TTM) | $-3.58 | $-12.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.12 | $50.70 |
| 52-week low | $0.755 | $3.50 |
| Distance from 52-week high | -94.55% | -92.84% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +313.22% |
| Average volume | 3.61M | 1.02M |
| Shares outstanding | 4.47M | 829.40K |
| Employees | 6 | 8 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bluejay Diagnostics
BJDX stock →Bluejay Diagnostics, Inc. operates as a medical diagnostics company.
Health Care · Medical/Dental Instruments · 6 employees
About Nexalin Technology
NXL stock →Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 8 employees
BJDX vs NXL FAQ
Which is bigger, Bluejay Diagnostics or Nexalin Technology?
Bluejay Diagnostics (BJDX) is larger, with a market capitalization of $3.68M compared with $3.01M for Nexalin Technology (NXL).
Are Bluejay Diagnostics and Nexalin Technology in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Bluejay Diagnostics and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Nexalin Technology.